BIOPHARMA CREDIT PLC

Capital/Financing Update • Apr 23, 2018

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 7037L

BioPharma Credit PLC

23 April 2018

BIOPHARMA CREDIT PLC

("BIOPHARMA CREDIT" OR THE "COMPANY")

NEW INVESTMENT

BioPharma Credit PLC (LSE: BPCR), a specialist life sciences debt investor, is pleased to announce that on 20 April 2018, it entered into a definitive senior-secured term-loan agreement as lead investor and collateral agent for a US$315 million loan to a commercial stage, private, specialty pharmaceutical company with pro-forma annual sales of approximately US$250 million. The borrower is a developer and marketer of multiple patent-protected specialty pharmaceutical products. BioPharma Credit PLC will provide US$194 million of capital and co-investors will provide US$121 million.  Key terms of the financing include a 5 year final maturity and a high-single-digit floating coupon. At this time, BPCR is unable to provide additional information on the borrower or the transaction.  The funding is expected to close within the next 15 days, at which point the Company will provide additional information. The funding will be completed out of the assets attributable to the ordinary shares of the Company only.

-Ends-

Link Company Matters Limited

Company Secretary

23 April 2018

Enquiries:

Buchanan

David Rydell/Mark Court/Jamie Hooper/Henry Wilson

+44 (0) 20 7466 5000

Biopharmacredit@buchanan.uk.com

Notes to Editors:

BioPharma Credit PLC is London's only listed specialist investor in debt from the life sciences industry and joined the LSE on 27 March 2017. The Company seeks to provide long-term shareholder returns, principally in the form of sustainable income distributions from exposure to the life sciences industry. The Company seeks to achieve this objective primarily through investments in debt assets secured by royalties or other cash flows derived from the sales of approved life sciences products.

LEI: 213800AV55PYXAS7SY24

This announcement contains Inside Information as defined under the Market Abuse Regulation (EU) No. 596/2014.

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCLFFSLSIIFFIT